# eye Aggregated by Superinsight from public-domain sources, as of 2026-08-27. Domain: va. --- ## DC 6000 — Choroidopathy, including uveitis, iritis, cyclitis, or choroiditis · Diseases of the Eye {#6000} *38 C.F.R. § 4.79, Diagnostic Code 6000* Official source: 6000 Choroidopathy, including uveitis, iritis, cyclitis, or choroiditis. General Rating Formula for Diseases of the Eye: Evaluate on the basis of either visual impairment due to the particular condition or on incapacitating episodes, whichever results in a higher evaluation With documented incapacitating episodes requiring 7 or more treatment visits for an eye condition during the past 12 months — 60 percent. With documented incapacitating episodes requiring at least 5 but less than 7 treatment visits for an eye condition during the past 12 months — 40 percent. With documented incapacitating episodes requiring at least 3 but less than 5 treatment visits for an eye condition during the past 12 months — 20 percent. With documented incapacitating episodes requiring at least 1 but less than 3 treatment visits for an eye condition during the past 12 months — 10 percent. Note (1): For the purposes of evaluation under 38 CFR 4.79, an incapacitating episode is an eye condition severe enough to require a clinic visit to a provider specifically for treatment purposes Note (2): Examples of treatment may include but are not limited to: Systemic immunosuppressants or biologic agents; intravitreal or periocular injections; laser treatments; or other surgical interventions Note (3): For the purposes of evaluating visual impairment due to the particular condition, refer to 38 CFR 4.75-4.78 and to § 4.79, diagnostic codes 6061-6091 --- ## DC 6001 — Keratopathy · Diseases of the Eye {#6001} *38 C.F.R. § 4.79, Diagnostic Code 6001* Official source: 6001 Keratopathy. General Rating Formula for Diseases of the Eye: Evaluate on the basis of either visual impairment due to the particular condition or on incapacitating episodes, whichever results in a higher evaluation With documented incapacitating episodes requiring 7 or more treatment visits for an eye condition during the past 12 months — 60 percent. With documented incapacitating episodes requiring at least 5 but less than 7 treatment visits for an eye condition during the past 12 months — 40 percent. With documented incapacitating episodes requiring at least 3 but less than 5 treatment visits for an eye condition during the past 12 months — 20 percent. With documented incapacitating episodes requiring at least 1 but less than 3 treatment visits for an eye condition during the past 12 months — 10 percent. Note (1): For the purposes of evaluation under 38 CFR 4.79, an incapacitating episode is an eye condition severe enough to require a clinic visit to a provider specifically for treatment purposes Note (2): Examples of treatment may include but are not limited to: Systemic immunosuppressants or biologic agents; intravitreal or periocular injections; laser treatments; or other surgical interventions Note (3): For the purposes of evaluating visual impairment due to the particular condition, refer to 38 CFR 4.75-4.78 and to § 4.79, diagnostic codes 6061-6091 --- ## DC 6002 — Scleritis · Diseases of the Eye {#6002} *38 C.F.R. § 4.79, Diagnostic Code 6002* Official source: 6002 Scleritis. General Rating Formula for Diseases of the Eye: Evaluate on the basis of either visual impairment due to the particular condition or on incapacitating episodes, whichever results in a higher evaluation With documented incapacitating episodes requiring 7 or more treatment visits for an eye condition during the past 12 months — 60 percent. With documented incapacitating episodes requiring at least 5 but less than 7 treatment visits for an eye condition during the past 12 months — 40 percent. With documented incapacitating episodes requiring at least 3 but less than 5 treatment visits for an eye condition during the past 12 months — 20 percent. With documented incapacitating episodes requiring at least 1 but less than 3 treatment visits for an eye condition during the past 12 months — 10 percent. Note (1): For the purposes of evaluation under 38 CFR 4.79, an incapacitating episode is an eye condition severe enough to require a clinic visit to a provider specifically for treatment purposes Note (2): Examples of treatment may include but are not limited to: Systemic immunosuppressants or biologic agents; intravitreal or periocular injections; laser treatments; or other surgical interventions Note (3): For the purposes of evaluating visual impairment due to the particular condition, refer to 38 CFR 4.75-4.78 and to § 4.79, diagnostic codes 6061-6091 --- ## DC 6006 — Retinopathy or maculopathy not otherwise specified · Diseases of the Eye {#6006} *38 C.F.R. § 4.79, Diagnostic Code 6006* Official source: 6006 Retinopathy or maculopathy not otherwise specified General Rating Formula for Diseases of the Eye: Evaluate on the basis of either visual impairment due to the particular condition or on incapacitating episodes, whichever results in a higher evaluation With documented incapacitating episodes requiring 7 or more treatment visits for an eye condition during the past 12 months — 60 percent. With documented incapacitating episodes requiring at least 5 but less than 7 treatment visits for an eye condition during the past 12 months — 40 percent. With documented incapacitating episodes requiring at least 3 but less than 5 treatment visits for an eye condition during the past 12 months — 20 percent. With documented incapacitating episodes requiring at least 1 but less than 3 treatment visits for an eye condition during the past 12 months — 10 percent. Note (1): For the purposes of evaluation under 38 CFR 4.79, an incapacitating episode is an eye condition severe enough to require a clinic visit to a provider specifically for treatment purposes Note (2): Examples of treatment may include but are not limited to: Systemic immunosuppressants or biologic agents; intravitreal or periocular injections; laser treatments; or other surgical interventions Note (3): For the purposes of evaluating visual impairment due to the particular condition, refer to 38 CFR 4.75-4.78 and to § 4.79, diagnostic codes 6061-6091 --- ## DC 6007 — Intraocular hemorrhage · Diseases of the Eye {#6007} *38 C.F.R. § 4.79, Diagnostic Code 6007* Official source: 6007 Intraocular hemorrhage. General Rating Formula for Diseases of the Eye: Evaluate on the basis of either visual impairment due to the particular condition or on incapacitating episodes, whichever results in a higher evaluation With documented incapacitating episodes requiring 7 or more treatment visits for an eye condition during the past 12 months — 60 percent. With documented incapacitating episodes requiring at least 5 but less than 7 treatment visits for an eye condition during the past 12 months — 40 percent. With documented incapacitating episodes requiring at least 3 but less than 5 treatment visits for an eye condition during the past 12 months — 20 percent. With documented incapacitating episodes requiring at least 1 but less than 3 treatment visits for an eye condition during the past 12 months — 10 percent. Note (1): For the purposes of evaluation under 38 CFR 4.79, an incapacitating episode is an eye condition severe enough to require a clinic visit to a provider specifically for treatment purposes Note (2): Examples of treatment may include but are not limited to: Systemic immunosuppressants or biologic agents; intravitreal or periocular injections; laser treatments; or other surgical interventions Note (3): For the purposes of evaluating visual impairment due to the particular condition, refer to 38 CFR 4.75-4.78 and to § 4.79, diagnostic codes 6061-6091 --- ## DC 6008 — Detachment of retina · Diseases of the Eye {#6008} *38 C.F.R. § 4.79, Diagnostic Code 6008* Official source: 6008 Detachment of retina. General Rating Formula for Diseases of the Eye: Evaluate on the basis of either visual impairment due to the particular condition or on incapacitating episodes, whichever results in a higher evaluation With documented incapacitating episodes requiring 7 or more treatment visits for an eye condition during the past 12 months — 60 percent. With documented incapacitating episodes requiring at least 5 but less than 7 treatment visits for an eye condition during the past 12 months — 40 percent. With documented incapacitating episodes requiring at least 3 but less than 5 treatment visits for an eye condition during the past 12 months — 20 percent. With documented incapacitating episodes requiring at least 1 but less than 3 treatment visits for an eye condition during the past 12 months — 10 percent. Note (1): For the purposes of evaluation under 38 CFR 4.79, an incapacitating episode is an eye condition severe enough to require a clinic visit to a provider specifically for treatment purposes Note (2): Examples of treatment may include but are not limited to: Systemic immunosuppressants or biologic agents; intravitreal or periocular injections; laser treatments; or other surgical interventions Note (3): For the purposes of evaluating visual impairment due to the particular condition, refer to 38 CFR 4.75-4.78 and to § 4.79, diagnostic codes 6061-6091 --- ## DC 6009 — Unhealed eye injury · Diseases of the Eye {#6009} *38 C.F.R. § 4.79, Diagnostic Code 6009* Official source: 6009 Unhealed eye injury. Note: This code includes orbital trauma, as well as penetrating or non-penetrating eye injury General Rating Formula for Diseases of the Eye: Evaluate on the basis of either visual impairment due to the particular condition or on incapacitating episodes, whichever results in a higher evaluation With documented incapacitating episodes requiring 7 or more treatment visits for an eye condition during the past 12 months — 60 percent. With documented incapacitating episodes requiring at least 5 but less than 7 treatment visits for an eye condition during the past 12 months — 40 percent. With documented incapacitating episodes requiring at least 3 but less than 5 treatment visits for an eye condition during the past 12 months — 20 percent. With documented incapacitating episodes requiring at least 1 but less than 3 treatment visits for an eye condition during the past 12 months — 10 percent. Note (1): For the purposes of evaluation under 38 CFR 4.79, an incapacitating episode is an eye condition severe enough to require a clinic visit to a provider specifically for treatment purposes Note (2): Examples of treatment may include but are not limited to: Systemic immunosuppressants or biologic agents; intravitreal or periocular injections; laser treatments; or other surgical interventions Note (3): For the purposes of evaluating visual impairment due to the particular condition, refer to 38 CFR 4.75-4.78 and to § 4.79, diagnostic codes 6061-6091 --- ## DC 6010 — Tuberculosis of eye · Diseases of the Eye {#6010} *38 C.F.R. § 4.79, Diagnostic Code 6010* Official source: 6010 Tuberculosis of eye: Active — 100 percent. Inactive: Evaluate under § 4.88c or § 4.89 of this part, whichever is appropriate --- ## DC 6011 — Retinal scars, atrophy, or irregularities · Diseases of the Eye {#6011} *38 C.F.R. § 4.79, Diagnostic Code 6011* Official source: 6011 Retinal scars, atrophy, or irregularities: Localized scars, atrophy, or irregularities of the retina, unilateral or bilateral, that are centrally located and that result in an irregular, duplicated, enlarged, or diminished image — 10 percent. Alternatively, evaluate based on the General Rating Formula for Diseases of the Eye, if this would result in a higher evaluation General Rating Formula for Diseases of the Eye: Evaluate on the basis of either visual impairment due to the particular condition or on incapacitating episodes, whichever results in a higher evaluation With documented incapacitating episodes requiring 7 or more treatment visits for an eye condition during the past 12 months — 60 percent. With documented incapacitating episodes requiring at least 5 but less than 7 treatment visits for an eye condition during the past 12 months — 40 percent. With documented incapacitating episodes requiring at least 3 but less than 5 treatment visits for an eye condition during the past 12 months — 20 percent. With documented incapacitating episodes requiring at least 1 but less than 3 treatment visits for an eye condition during the past 12 months — 10 percent. Note (1): For the purposes of evaluation under 38 CFR 4.79, an incapacitating episode is an eye condition severe enough to require a clinic visit to a provider specifically for treatment purposes Note (2): Examples of treatment may include but are not limited to: Systemic immunosuppressants or biologic agents; intravitreal or periocular injections; laser treatments; or other surgical interventions Note (3): For the purposes of evaluating visual impairment due to the particular condition, refer to 38 CFR 4.75-4.78 and to § 4.79, diagnostic codes 6061-6091 --- ## DC 6012 — Angle-closure glaucoma · Diseases of the Eye {#6012} *38 C.F.R. § 4.79, Diagnostic Code 6012* Official source: 6012 Angle-closure glaucoma Evaluate under the General Rating Formula for Diseases of the Eye. Minimum evaluation if continuous medication is required — 10 percent. General Rating Formula for Diseases of the Eye: Evaluate on the basis of either visual impairment due to the particular condition or on incapacitating episodes, whichever results in a higher evaluation With documented incapacitating episodes requiring 7 or more treatment visits for an eye condition during the past 12 months — 60 percent. With documented incapacitating episodes requiring at least 5 but less than 7 treatment visits for an eye condition during the past 12 months — 40 percent. With documented incapacitating episodes requiring at least 3 but less than 5 treatment visits for an eye condition during the past 12 months — 20 percent. With documented incapacitating episodes requiring at least 1 but less than 3 treatment visits for an eye condition during the past 12 months — 10 percent. Note (1): For the purposes of evaluation under 38 CFR 4.79, an incapacitating episode is an eye condition severe enough to require a clinic visit to a provider specifically for treatment purposes Note (2): Examples of treatment may include but are not limited to: Systemic immunosuppressants or biologic agents; intravitreal or periocular injections; laser treatments; or other surgical interventions Note (3): For the purposes of evaluating visual impairment due to the particular condition, refer to 38 CFR 4.75-4.78 and to § 4.79, diagnostic codes 6061-6091 --- ## DC 6013 — Open-angle glaucoma · Diseases of the Eye {#6013} *38 C.F.R. § 4.79, Diagnostic Code 6013* Official source: 6013 Open-angle glaucoma Evaluate under the General Rating Formula for Diseases of the Eye. Minimum evaluation if continuous medication is required — 10 percent. General Rating Formula for Diseases of the Eye: Evaluate on the basis of either visual impairment due to the particular condition or on incapacitating episodes, whichever results in a higher evaluation With documented incapacitating episodes requiring 7 or more treatment visits for an eye condition during the past 12 months — 60 percent. With documented incapacitating episodes requiring at least 5 but less than 7 treatment visits for an eye condition during the past 12 months — 40 percent. With documented incapacitating episodes requiring at least 3 but less than 5 treatment visits for an eye condition during the past 12 months — 20 percent. With documented incapacitating episodes requiring at least 1 but less than 3 treatment visits for an eye condition during the past 12 months — 10 percent. Note (1): For the purposes of evaluation under 38 CFR 4.79, an incapacitating episode is an eye condition severe enough to require a clinic visit to a provider specifically for treatment purposes Note (2): Examples of treatment may include but are not limited to: Systemic immunosuppressants or biologic agents; intravitreal or periocular injections; laser treatments; or other surgical interventions Note (3): For the purposes of evaluating visual impairment due to the particular condition, refer to 38 CFR 4.75-4.78 and to § 4.79, diagnostic codes 6061-6091 --- ## DC 6014 — Malignant neoplasms of the eye, orbit, and adnexa (excluding skin) · Diseases of the Eye {#6014} *38 C.F.R. § 4.79, Diagnostic Code 6014* Official source: 6014 Malignant neoplasms of the eye, orbit, and adnexa (excluding skin): Malignant neoplasms of the eye, orbit, and adnexa (excluding skin) that require therapy that is comparable to those used for systemic malignancies, i.e., systemic chemotherapy, X-ray therapy more extensive than to the area of the eye, or surgery more extensive than enucleation — 100 percent. Note: Continue the 100 percent rating beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy, or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating will be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination will be subject to the provisions of § 3.105(e) of this chapter. If there has been no local recurrence or metastasis, evaluate based on residuals Malignant neoplasms of the eye, orbit, and adnexa (excluding skin) that do not require therapy comparable to that for systemic malignancies: Separately evaluate visual and nonvisual impairment, e.g., disfigurement (diagnostic code 7800), and combine the evaluations --- ## DC 6015 — Benign neoplasms of the eye, orbit, and adnexa (excluding skin) · Diseases of the Eye {#6015} *38 C.F.R. § 4.79, Diagnostic Code 6015* Official source: 6015 Benign neoplasms of the eye, orbit, and adnexa (excluding skin): Separately evaluate visual and nonvisual impairment, e.g., disfigurement (diagnostic code 7800), and combine the evaluations General Rating Formula for Diseases of the Eye: Evaluate on the basis of either visual impairment due to the particular condition or on incapacitating episodes, whichever results in a higher evaluation With documented incapacitating episodes requiring 7 or more treatment visits for an eye condition during the past 12 months — 60 percent. With documented incapacitating episodes requiring at least 5 but less than 7 treatment visits for an eye condition during the past 12 months — 40 percent. With documented incapacitating episodes requiring at least 3 but less than 5 treatment visits for an eye condition during the past 12 months — 20 percent. With documented incapacitating episodes requiring at least 1 but less than 3 treatment visits for an eye condition during the past 12 months — 10 percent. Note (1): For the purposes of evaluation under 38 CFR 4.79, an incapacitating episode is an eye condition severe enough to require a clinic visit to a provider specifically for treatment purposes Note (2): Examples of treatment may include but are not limited to: Systemic immunosuppressants or biologic agents; intravitreal or periocular injections; laser treatments; or other surgical interventions Note (3): For the purposes of evaluating visual impairment due to the particular condition, refer to 38 CFR 4.75-4.78 and to § 4.79, diagnostic codes 6061-6091 --- ## DC 6016 — Nystagmus, central · Diseases of the Eye {#6016} *38 C.F.R. § 4.79, Diagnostic Code 6016* Official source: 6016 Nystagmus, central — 10 percent. --- ## DC 6017 — Trachomatous conjunctivitis · Diseases of the Eye {#6017} *38 C.F.R. § 4.79, Diagnostic Code 6017* Official source: 6017 Trachomatous conjunctivitis: Active: Evaluate under the General Rating Formula for Diseases of the Eye, minimum rating — 30 percent. Inactive: Evaluate based on residuals, such as visual impairment and disfigurement (diagnostic code 7800) General Rating Formula for Diseases of the Eye: Evaluate on the basis of either visual impairment due to the particular condition or on incapacitating episodes, whichever results in a higher evaluation With documented incapacitating episodes requiring 7 or more treatment visits for an eye condition during the past 12 months — 60 percent. With documented incapacitating episodes requiring at least 5 but less than 7 treatment visits for an eye condition during the past 12 months — 40 percent. With documented incapacitating episodes requiring at least 3 but less than 5 treatment visits for an eye condition during the past 12 months — 20 percent. With documented incapacitating episodes requiring at least 1 but less than 3 treatment visits for an eye condition during the past 12 months — 10 percent. Note (1): For the purposes of evaluation under 38 CFR 4.79, an incapacitating episode is an eye condition severe enough to require a clinic visit to a provider specifically for treatment purposes Note (2): Examples of treatment may include but are not limited to: Systemic immunosuppressants or biologic agents; intravitreal or periocular injections; laser treatments; or other surgical interventions Note (3): For the purposes of evaluating visual impairment due to the particular condition, refer to 38 CFR 4.75-4.78 and to § 4.79, diagnostic codes 6061-6091 --- ## DC 6018 — Chronic conjunctivitis (nontrachomatous) · Diseases of the Eye {#6018} *38 C.F.R. § 4.79, Diagnostic Code 6018* Official source: 6018 Chronic conjunctivitis (nontrachomatous): Active: Evaluate under the General Rating Formula for Diseases of the Eye, minimum rating — 10 percent. Inactive: Evaluate based on residuals, such as visual impairment and disfigurement (diagnostic code 7800) General Rating Formula for Diseases of the Eye: Evaluate on the basis of either visual impairment due to the particular condition or on incapacitating episodes, whichever results in a higher evaluation With documented incapacitating episodes requiring 7 or more treatment visits for an eye condition during the past 12 months — 60 percent. With documented incapacitating episodes requiring at least 5 but less than 7 treatment visits for an eye condition during the past 12 months — 40 percent. With documented incapacitating episodes requiring at least 3 but less than 5 treatment visits for an eye condition during the past 12 months — 20 percent. With documented incapacitating episodes requiring at least 1 but less than 3 treatment visits for an eye condition during the past 12 months — 10 percent. Note (1): For the purposes of evaluation under 38 CFR 4.79, an incapacitating episode is an eye condition severe enough to require a clinic visit to a provider specifically for treatment purposes Note (2): Examples of treatment may include but are not limited to: Systemic immunosuppressants or biologic agents; intravitreal or periocular injections; laser treatments; or other surgical interventions Note (3): For the purposes of evaluating visual impairment due to the particular condition, refer to 38 CFR 4.75-4.78 and to § 4.79, diagnostic codes 6061-6091 --- ## DC 6019 — Ptosis, unilateral or bilateral · Diseases of the Eye {#6019} *38 C.F.R. § 4.79, Diagnostic Code 6019* Official source: 6019 Ptosis, unilateral or bilateral: Evaluate based on visual impairment or, in the absence of visual impairment, on disfigurement (diagnostic code 7800). General Rating Formula for Diseases of the Eye: Evaluate on the basis of either visual impairment due to the particular condition or on incapacitating episodes, whichever results in a higher evaluation With documented incapacitating episodes requiring 7 or more treatment visits for an eye condition during the past 12 months — 60 percent. With documented incapacitating episodes requiring at least 5 but less than 7 treatment visits for an eye condition during the past 12 months — 40 percent. With documented incapacitating episodes requiring at least 3 but less than 5 treatment visits for an eye condition during the past 12 months — 20 percent. With documented incapacitating episodes requiring at least 1 but less than 3 treatment visits for an eye condition during the past 12 months — 10 percent. Note (1): For the purposes of evaluation under 38 CFR 4.79, an incapacitating episode is an eye condition severe enough to require a clinic visit to a provider specifically for treatment purposes Note (2): Examples of treatment may include but are not limited to: Systemic immunosuppressants or biologic agents; intravitreal or periocular injections; laser treatments; or other surgical interventions Note (3): For the purposes of evaluating visual impairment due to the particular condition, refer to 38 CFR 4.75-4.78 and to § 4.79, diagnostic codes 6061-6091 --- ## DC 6020 — Ectropion · Diseases of the Eye {#6020} *38 C.F.R. § 4.79, Diagnostic Code 6020* Official source: 6020 Ectropion: Bilateral — 20 percent. Unilateral — 10 percent. --- ## DC 6021 — Entropion · Diseases of the Eye {#6021} *38 C.F.R. § 4.79, Diagnostic Code 6021* Official source: 6021 Entropion: Bilateral — 20 percent. Unilateral — 10 percent. --- ## DC 6022 — Lagophthalmos · Diseases of the Eye {#6022} *38 C.F.R. § 4.79, Diagnostic Code 6022* Official source: 6022 Lagophthalmos: Bilateral — 20 percent. Unilateral — 10 percent. --- ## DC 6023 — Loss of eyebrows, complete, unilateral or bilateral · Diseases of the Eye {#6023} *38 C.F.R. § 4.79, Diagnostic Code 6023* Official source: 6023 Loss of eyebrows, complete, unilateral or bilateral — 10 percent. --- ## DC 6024 — Loss of eyelashes, complete, unilateral or bilateral · Diseases of the Eye {#6024} *38 C.F.R. § 4.79, Diagnostic Code 6024* Official source: 6024 Loss of eyelashes, complete, unilateral or bilateral — 10 percent. --- ## DC 6025 — Disorders of the lacrimal apparatus (epiphora, dacryocystitis, etc.) · Diseases of the Eye {#6025} *38 C.F.R. § 4.79, Diagnostic Code 6025* Official source: 6025 Disorders of the lacrimal apparatus (epiphora, dacryocystitis, etc.): Bilateral — 20 percent. Unilateral — 10 percent. --- ## DC 6026 — Optic neuropathy · Diseases of the Eye {#6026} *38 C.F.R. § 4.79, Diagnostic Code 6026* Official source: 6026 Optic neuropathy General Rating Formula for Diseases of the Eye: Evaluate on the basis of either visual impairment due to the particular condition or on incapacitating episodes, whichever results in a higher evaluation With documented incapacitating episodes requiring 7 or more treatment visits for an eye condition during the past 12 months — 60 percent. With documented incapacitating episodes requiring at least 5 but less than 7 treatment visits for an eye condition during the past 12 months — 40 percent. With documented incapacitating episodes requiring at least 3 but less than 5 treatment visits for an eye condition during the past 12 months — 20 percent. With documented incapacitating episodes requiring at least 1 but less than 3 treatment visits for an eye condition during the past 12 months — 10 percent. Note (1): For the purposes of evaluation under 38 CFR 4.79, an incapacitating episode is an eye condition severe enough to require a clinic visit to a provider specifically for treatment purposes Note (2): Examples of treatment may include but are not limited to: Systemic immunosuppressants or biologic agents; intravitreal or periocular injections; laser treatments; or other surgical interventions Note (3): For the purposes of evaluating visual impairment due to the particular condition, refer to 38 CFR 4.75-4.78 and to § 4.79, diagnostic codes 6061-6091 --- ## DC 6027 — Cataract · Diseases of the Eye {#6027} *38 C.F.R. § 4.79, Diagnostic Code 6027* Official source: 6027 Cataract: Preoperative: Evaluate under the General Rating Formula for Diseases of the Eye Postoperative: If a replacement lens is present (pseudophakia), evaluate under the General Rating Formula for Diseases of the Eye. If there is no replacement lens, evaluate based on aphakia (diagnostic code 6029) General Rating Formula for Diseases of the Eye: Evaluate on the basis of either visual impairment due to the particular condition or on incapacitating episodes, whichever results in a higher evaluation With documented incapacitating episodes requiring 7 or more treatment visits for an eye condition during the past 12 months — 60 percent. With documented incapacitating episodes requiring at least 5 but less than 7 treatment visits for an eye condition during the past 12 months — 40 percent. With documented incapacitating episodes requiring at least 3 but less than 5 treatment visits for an eye condition during the past 12 months — 20 percent. With documented incapacitating episodes requiring at least 1 but less than 3 treatment visits for an eye condition during the past 12 months — 10 percent. Note (1): For the purposes of evaluation under 38 CFR 4.79, an incapacitating episode is an eye condition severe enough to require a clinic visit to a provider specifically for treatment purposes Note (2): Examples of treatment may include but are not limited to: Systemic immunosuppressants or biologic agents; intravitreal or periocular injections; laser treatments; or other surgical interventions Note (3): For the purposes of evaluating visual impairment due to the particular condition, refer to 38 CFR 4.75-4.78 and to § 4.79, diagnostic codes 6061-6091 --- ## DC 6029 — Aphakia or dislocation of crystalline lens · Diseases of the Eye {#6029} *38 C.F.R. § 4.79, Diagnostic Code 6029* Official source: 6029 Aphakia or dislocation of crystalline lens: Evaluate based on visual impairment, and elevate the resulting level of visual impairment one step. Minimum (unilateral or bilateral) — 30 percent. --- ## DC 6030 — Paralysis of accommodation (due to neuropathy of the Oculomotor Nerve (cranial nerve III)) · Diseases of the Eye {#6030} *38 C.F.R. § 4.79, Diagnostic Code 6030* Official source: 6030 Paralysis of accommodation (due to neuropathy of the Oculomotor Nerve (cranial nerve III)). — 20 percent. --- ## DC 6032 — Loss of eyelids, partial or complete · Diseases of the Eye {#6032} *38 C.F.R. § 4.79, Diagnostic Code 6032* Official source: 6032 Loss of eyelids, partial or complete: Separately evaluate both visual impairment due to eyelid loss and nonvisual impairment, e.g., disfigurement (diagnostic code 7800), and combine the evaluations. General Rating Formula for Diseases of the Eye: Evaluate on the basis of either visual impairment due to the particular condition or on incapacitating episodes, whichever results in a higher evaluation With documented incapacitating episodes requiring 7 or more treatment visits for an eye condition during the past 12 months — 60 percent. With documented incapacitating episodes requiring at least 5 but less than 7 treatment visits for an eye condition during the past 12 months — 40 percent. With documented incapacitating episodes requiring at least 3 but less than 5 treatment visits for an eye condition during the past 12 months — 20 percent. With documented incapacitating episodes requiring at least 1 but less than 3 treatment visits for an eye condition during the past 12 months — 10 percent. Note (1): For the purposes of evaluation under 38 CFR 4.79, an incapacitating episode is an eye condition severe enough to require a clinic visit to a provider specifically for treatment purposes Note (2): Examples of treatment may include but are not limited to: Systemic immunosuppressants or biologic agents; intravitreal or periocular injections; laser treatments; or other surgical interventions Note (3): For the purposes of evaluating visual impairment due to the particular condition, refer to 38 CFR 4.75-4.78 and to § 4.79, diagnostic codes 6061-6091 --- ## DC 6034 — Pterygium · Diseases of the Eye {#6034} *38 C.F.R. § 4.79, Diagnostic Code 6034* Official source: 6034 Pterygium: Evaluate under the General Rating Formula for Diseases of the Eye, disfigurement (diagnostic code 7800), conjunctivitis (diagnostic code 6018), etc., depending on the particular findings, and combine in accordance with § 4.25 General Rating Formula for Diseases of the Eye: Evaluate on the basis of either visual impairment due to the particular condition or on incapacitating episodes, whichever results in a higher evaluation With documented incapacitating episodes requiring 7 or more treatment visits for an eye condition during the past 12 months — 60 percent. With documented incapacitating episodes requiring at least 5 but less than 7 treatment visits for an eye condition during the past 12 months — 40 percent. With documented incapacitating episodes requiring at least 3 but less than 5 treatment visits for an eye condition during the past 12 months — 20 percent. With documented incapacitating episodes requiring at least 1 but less than 3 treatment visits for an eye condition during the past 12 months — 10 percent. Note (1): For the purposes of evaluation under 38 CFR 4.79, an incapacitating episode is an eye condition severe enough to require a clinic visit to a provider specifically for treatment purposes Note (2): Examples of treatment may include but are not limited to: Systemic immunosuppressants or biologic agents; intravitreal or periocular injections; laser treatments; or other surgical interventions Note (3): For the purposes of evaluating visual impairment due to the particular condition, refer to 38 CFR 4.75-4.78 and to § 4.79, diagnostic codes 6061-6091 --- ## DC 6035 — Keratoconus · Diseases of the Eye {#6035} *38 C.F.R. § 4.79, Diagnostic Code 6035* Official source: 6035 Keratoconus General Rating Formula for Diseases of the Eye: Evaluate on the basis of either visual impairment due to the particular condition or on incapacitating episodes, whichever results in a higher evaluation With documented incapacitating episodes requiring 7 or more treatment visits for an eye condition during the past 12 months — 60 percent. With documented incapacitating episodes requiring at least 5 but less than 7 treatment visits for an eye condition during the past 12 months — 40 percent. With documented incapacitating episodes requiring at least 3 but less than 5 treatment visits for an eye condition during the past 12 months — 20 percent. With documented incapacitating episodes requiring at least 1 but less than 3 treatment visits for an eye condition during the past 12 months — 10 percent. Note (1): For the purposes of evaluation under 38 CFR 4.79, an incapacitating episode is an eye condition severe enough to require a clinic visit to a provider specifically for treatment purposes Note (2): Examples of treatment may include but are not limited to: Systemic immunosuppressants or biologic agents; intravitreal or periocular injections; laser treatments; or other surgical interventions Note (3): For the purposes of evaluating visual impairment due to the particular condition, refer to 38 CFR 4.75-4.78 and to § 4.79, diagnostic codes 6061-6091 --- ## DC 6036 — Status post corneal transplant · Diseases of the Eye {#6036} *38 C.F.R. § 4.79, Diagnostic Code 6036* Official source: 6036 Status post corneal transplant: Evaluate under the General Rating Formula for Diseases of the Eye. Minimum, if there is pain, photophobia, and glare sensitivity — 10 percent. General Rating Formula for Diseases of the Eye: Evaluate on the basis of either visual impairment due to the particular condition or on incapacitating episodes, whichever results in a higher evaluation With documented incapacitating episodes requiring 7 or more treatment visits for an eye condition during the past 12 months — 60 percent. With documented incapacitating episodes requiring at least 5 but less than 7 treatment visits for an eye condition during the past 12 months — 40 percent. With documented incapacitating episodes requiring at least 3 but less than 5 treatment visits for an eye condition during the past 12 months — 20 percent. With documented incapacitating episodes requiring at least 1 but less than 3 treatment visits for an eye condition during the past 12 months — 10 percent. Note (1): For the purposes of evaluation under 38 CFR 4.79, an incapacitating episode is an eye condition severe enough to require a clinic visit to a provider specifically for treatment purposes Note (2): Examples of treatment may include but are not limited to: Systemic immunosuppressants or biologic agents; intravitreal or periocular injections; laser treatments; or other surgical interventions Note (3): For the purposes of evaluating visual impairment due to the particular condition, refer to 38 CFR 4.75-4.78 and to § 4.79, diagnostic codes 6061-6091 --- ## DC 6037 — Pinguecula · Diseases of the Eye {#6037} *38 C.F.R. § 4.79, Diagnostic Code 6037* Official source: 6037 Pinguecula: Evaluate based on disfigurement (diagnostic code 7800). General Rating Formula for Diseases of the Eye: Evaluate on the basis of either visual impairment due to the particular condition or on incapacitating episodes, whichever results in a higher evaluation With documented incapacitating episodes requiring 7 or more treatment visits for an eye condition during the past 12 months — 60 percent. With documented incapacitating episodes requiring at least 5 but less than 7 treatment visits for an eye condition during the past 12 months — 40 percent. With documented incapacitating episodes requiring at least 3 but less than 5 treatment visits for an eye condition during the past 12 months — 20 percent. With documented incapacitating episodes requiring at least 1 but less than 3 treatment visits for an eye condition during the past 12 months — 10 percent. Note (1): For the purposes of evaluation under 38 CFR 4.79, an incapacitating episode is an eye condition severe enough to require a clinic visit to a provider specifically for treatment purposes Note (2): Examples of treatment may include but are not limited to: Systemic immunosuppressants or biologic agents; intravitreal or periocular injections; laser treatments; or other surgical interventions Note (3): For the purposes of evaluating visual impairment due to the particular condition, refer to 38 CFR 4.75-4.78 and to § 4.79, diagnostic codes 6061-6091 --- ## DC 6040 — Diabetic retinopathy · Diseases of the Eye {#6040} *38 C.F.R. § 4.79, Diagnostic Code 6040* Official source: 6040 Diabetic retinopathy General Rating Formula for Diseases of the Eye: Evaluate on the basis of either visual impairment due to the particular condition or on incapacitating episodes, whichever results in a higher evaluation With documented incapacitating episodes requiring 7 or more treatment visits for an eye condition during the past 12 months — 60 percent. With documented incapacitating episodes requiring at least 5 but less than 7 treatment visits for an eye condition during the past 12 months — 40 percent. With documented incapacitating episodes requiring at least 3 but less than 5 treatment visits for an eye condition during the past 12 months — 20 percent. With documented incapacitating episodes requiring at least 1 but less than 3 treatment visits for an eye condition during the past 12 months — 10 percent. Note (1): For the purposes of evaluation under 38 CFR 4.79, an incapacitating episode is an eye condition severe enough to require a clinic visit to a provider specifically for treatment purposes Note (2): Examples of treatment may include but are not limited to: Systemic immunosuppressants or biologic agents; intravitreal or periocular injections; laser treatments; or other surgical interventions Note (3): For the purposes of evaluating visual impairment due to the particular condition, refer to 38 CFR 4.75-4.78 and to § 4.79, diagnostic codes 6061-6091 --- ## DC 6042 — Retinal dystrophy (including retinitis pigmentosa, wet or dry macular degeneration, early-onset macular degeneration, rod and/or cone dystrophy) · Diseases of the Eye {#6042} *38 C.F.R. § 4.79, Diagnostic Code 6042* Official source: 6042 Retinal dystrophy (including retinitis pigmentosa, wet or dry macular degeneration, early-onset macular degeneration, rod and/or cone dystrophy) General Rating Formula for Diseases of the Eye: Evaluate on the basis of either visual impairment due to the particular condition or on incapacitating episodes, whichever results in a higher evaluation With documented incapacitating episodes requiring 7 or more treatment visits for an eye condition during the past 12 months — 60 percent. With documented incapacitating episodes requiring at least 5 but less than 7 treatment visits for an eye condition during the past 12 months — 40 percent. With documented incapacitating episodes requiring at least 3 but less than 5 treatment visits for an eye condition during the past 12 months — 20 percent. With documented incapacitating episodes requiring at least 1 but less than 3 treatment visits for an eye condition during the past 12 months — 10 percent. Note (1): For the purposes of evaluation under 38 CFR 4.79, an incapacitating episode is an eye condition severe enough to require a clinic visit to a provider specifically for treatment purposes Note (2): Examples of treatment may include but are not limited to: Systemic immunosuppressants or biologic agents; intravitreal or periocular injections; laser treatments; or other surgical interventions Note (3): For the purposes of evaluating visual impairment due to the particular condition, refer to 38 CFR 4.75-4.78 and to § 4.79, diagnostic codes 6061-6091 --- ## DC 6046 — Post-chiasmal disorders · Diseases of the Eye {#6046} *38 C.F.R. § 4.79, Diagnostic Code 6046* Official source: 6046 Post-chiasmal disorders Impairment of Central Visual Acuity General Rating Formula for Diseases of the Eye: Evaluate on the basis of either visual impairment due to the particular condition or on incapacitating episodes, whichever results in a higher evaluation With documented incapacitating episodes requiring 7 or more treatment visits for an eye condition during the past 12 months — 60 percent. With documented incapacitating episodes requiring at least 5 but less than 7 treatment visits for an eye condition during the past 12 months — 40 percent. With documented incapacitating episodes requiring at least 3 but less than 5 treatment visits for an eye condition during the past 12 months — 20 percent. With documented incapacitating episodes requiring at least 1 but less than 3 treatment visits for an eye condition during the past 12 months — 10 percent. Note (1): For the purposes of evaluation under 38 CFR 4.79, an incapacitating episode is an eye condition severe enough to require a clinic visit to a provider specifically for treatment purposes Note (2): Examples of treatment may include but are not limited to: Systemic immunosuppressants or biologic agents; intravitreal or periocular injections; laser treatments; or other surgical interventions Note (3): For the purposes of evaluating visual impairment due to the particular condition, refer to 38 CFR 4.75-4.78 and to § 4.79, diagnostic codes 6061-6091 --- ## DC 6061 — Anatomical loss of both eyes · Diseases of the Eye {#6061} *38 C.F.R. § 4.79, Diagnostic Code 6061* Official source: 6061 Anatomical loss of both eyes — 100 percent. --- ## DC 6062 — No more than light perception in both eyes · Diseases of the Eye {#6062} *38 C.F.R. § 4.79, Diagnostic Code 6062* Official source: 6062 No more than light perception in both eyes — 100 percent. --- ## DC 6063 — Anatomical loss of one eye · Diseases of the Eye {#6063} *38 C.F.R. § 4.79, Diagnostic Code 6063* Official source: 6063 Anatomical loss of one eye: In the other eye 5/200 (1.5/60) — 100 percent. In the other eye 10/200 (3/60) — 90 percent. In the other eye 15/200 (4.5/60) — 80 percent. In the other eye 20/200 (6/60) — 70 percent. In the other eye 20/100 (6/30) — 60 percent. In the other eye 20/70 (6/21) — 60 percent. In the other eye 20/50 (6/15) — 50 percent. In the other eye 20/40 (6/12) — 40 percent. --- ## DC 6064 — No more than light perception in one eye · Diseases of the Eye {#6064} *38 C.F.R. § 4.79, Diagnostic Code 6064* Official source: 6064 No more than light perception in one eye: In the other eye 5/200 (1.5/60) — 100 percent. In the other eye 10/200 (3/60) — 90 percent. In the other eye 15/200 (4.5/60) — 80 percent. In the other eye 20/200 (6/60) — 70 percent. In the other eye 20/100 (6/30) — 60 percent. In the other eye 20/70 (6/21) — 50 percent. In the other eye 20/50 (6/15) — 40 percent. In the other eye 20/40 (6/12) — 30 percent. --- ## DC 6065 — Vision in one eye 5/200 (1.5/60) · Diseases of the Eye {#6065} *38 C.F.R. § 4.79, Diagnostic Code 6065* Official source: 6065 Vision in one eye 5/200 (1.5/60): In the other eye 5/200 (1.5/60) — 100 percent. In the other eye 10/200 (3/60) — 90 percent. In the other eye 15/200 (4.5/60) — 80 percent. In the other eye 20/200 (6/60) — 70 percent. In the other eye 20/100 (6/30) — 60 percent. In the other eye 20/70 (6/21) — 50 percent. In the other eye 20/50 (6/15) — 40 percent. In the other eye 20/40 (6/12) — 30 percent. --- ## DC 6066 — Visual acuity in one eye 10/200 (3/60) or better · Diseases of the Eye {#6066} *38 C.F.R. § 4.79, Diagnostic Code 6066* Official source: 6066 Visual acuity in one eye 10/200 (3/60) or better: Vision in one eye 10/200 (3/60): In the other eye 10/200 (3/60) — 90 percent. In the other eye 15/200 (4.5/60) — 80 percent. In the other eye 20/200 (6/60) — 70 percent. In the other eye 20/100 (6/30) — 60 percent. In the other eye 20/70 (6/21) — 50 percent. In the other eye 20/50 (6/15) — 40 percent. In the other eye 20/40 (6/12) — 30 percent. Vision in one eye 15/200 (4.5/60): In the other eye 15/200 (4.5/60) — 80 percent. In the other eye 20/200 (6/60) — 70 percent. In the other eye 20/100 (6/30) — 60 percent. In the other eye 20/70 (6/21) — 40 percent. In the other eye 20/50 (6/15) — 30 percent. In the other eye 20/40 (6/12) — 20 percent. Vision in one eye 20/200 (6/60): In the other eye 20/200 (6/60) — 70 percent. In the other eye 20/100 (6/30) — 60 percent. In the other eye 20/70 (6/21) — 40 percent. In the other eye 20/50 (6/15) — 30 percent. In the other eye 20/40 (6/12) — 20 percent. Vision in one eye 20/100 (6/30): In the other eye 20/100 (6/30) — 50 percent. In the other eye 20/70 (6/21) — 30 percent. In the other eye 20/50 (6/15) — 20 percent. In the other eye 20/40 (6/12) — 10 percent. Vision in one eye 20/70 (6/21): In the other eye 20/70 (6/21) — 30 percent. In the other eye 20/50 (6/15) — 20 percent. In the other eye 20/40 (6/12) — 10 percent. Vision in one eye 20/50 (6/15): In the other eye 20/50 (6/15) — 10 percent. In the other eye 20/40 (6/12) — 10 percent. Vision in one eye 20/40 (6/12): In the other eye 20/40 (6/12) — 0 percent. Review for entitlement to special monthly compensation under 38 CFR 3.350. --- ## DC 6080 — Visual field defects · Ratings for Impairment of Visual Fields {#6080} *38 C.F.R. § 4.79, Diagnostic Code 6080* Official source: 6080 Visual field defects: Homonymous hemianopsia — 30 percent. Loss of temporal half of visual field: Bilateral — 30 percent. Unilateral — 10 percent. Or evaluate each affected eye as 20/70 (6/21) Loss of nasal half of visual field: Bilateral — 10 percent. Unilateral — 10 percent. Or evaluate each affected eye as 20/50 (6/15) Loss of inferior half of visual field: Bilateral — 30 percent. Unilateral — 10 percent. Or evaluate each affected eye as 20/70 (6/21) Loss of superior half of visual field: Bilateral — 10 percent. Unilateral — 10 percent. Or evaluate each affected eye as 20/50 (6/15) Concentric contraction of visual field: With remaining field of 5 degrees: Bilateral — 100 percent. Unilateral — 30 percent. Or evaluate each affected eye as 5/200 (1.5/60) With remaining field of 6 to 15 degrees: Bilateral — 70 percent. Unilateral — 20 percent. Or evaluate each affected eye as 20/200 (6/60) With remaining field of 16 to 30 degrees: Bilateral — 50 percent. Unilateral — 10 percent. Or evaluate each affected eye as 20/100 (6/30) With remaining field of 31 to 45 degrees: Bilateral — 30 percent. Unilateral — 10 percent. Or evaluate each affected eye as 20/70 (6/21) With remaining field of 46 to 60 degrees: Bilateral — 10 percent. Unilateral — 10 percent. Or evaluate each affected eye as 20/50 (6/15) --- ## DC 6081 — Scotoma, unilateral · Ratings for Impairment of Visual Fields {#6081} *38 C.F.R. § 4.79, Diagnostic Code 6081* Official source: 6081 Scotoma, unilateral: Minimum, with scotoma affecting at least one-quarter of the visual field (quadrantanopsia) or with centrally located scotoma of any size — 10 percent. Alternatively, evaluate based on visual impairment due to scotoma, if that would result in a higher evaluation Review for entitlement to special monthly compensation under 38 CFR 3.350. --- ## DC 6090 — Diplopia (double vision) · Ratings for Impairment of Muscle Function {#6090} *38 C.F.R. § 4.79, Diagnostic Code 6090* Official source: 6090 Diplopia (double vision): (a) Central 20 degrees — 5/200 (1.5/60) (b) 21 degrees to 30 degrees (1) Down — 15/200 (4.5/60) (2) Lateral — 20/100 (6/30) (3) Up — 20/70 (6/21) (c) 31 degrees to 40 degrees (1) Down — 20/200 (6/60) (2) Lateral — 20/70 (6/21) (3) Up — 20/40 (6/12) Note: In accordance with 38 CFR 4.31, diplopia that is occasional or that is correctable with spectacles is evaluated at 0 percent. --- ## DC 6091 — Symblepharon · Ratings for Impairment of Muscle Function {#6091} *38 C.F.R. § 4.79, Diagnostic Code 6091* Official source: 6091 Symblepharon: Evaluate under the General Rating Formula for Diseases of the Eye, lagophthalmos (diagnostic code 6022), disfigurement (diagnostic code 7800), etc., depending on the particular findings, and combine in accordance with § 4.25